NEW YORK (GenomeWeb) – Caris Life Sciences today announced a strategic collaboration with Debiopharm International to develop a companion diagnostic for an oncology drug being developed by the Swiss biopharmaceuticals firm.
The firms will use Caris' Molecular Intelligence (MI) Transcriptome assay for mRNA analysis to detect rare fibroblast growth factor receptor (FGFR) fusions and identify eligible patients for Debiopharm's FUZE phase II clinical trial of Debio 1347, a selective FGFR inhibitor.